Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor.
Plantevin Krenitsky, V., Nadolny, L., Delgado, M., Ayala, L., Clareen, S.S., Hilgraf, R., Albers, R., Hegde, S., D'Sidocky, N., Sapienza, J., Wright, J., McCarrick, M., Bahmanyar, S., Chamberlain, P., Delker, S.L., Muir, J., Giegel, D., Xu, L., Celeridad, M., Lachowitzer, J., Bennett, B., Moghaddam, M., Khatsenko, O., Katz, J., Fan, R., Bai, A., Tang, Y., Shirley, M.A., Benish, B., Bodine, T., Blease, K., Raymon, H., Cathers, B.E., Satoh, Y.(2012) Bioorg Med Chem Lett 22: 1433-1438
- PubMed: 22244937 
- DOI: 10.1016/j.bmcl.2011.12.027
- Primary Citation of Related Structures:  
3TTI - PubMed Abstract: 
In this Letter we describe the discovery of potent, selective, and orally active aminopurine JNK inhibitors. Improving the physico-chemical properties as well as increasing the potency and selectivity of a subseries with rat plasma exposure, led to the i ...